Expert Opinion on Drug Metabolism & Toxicology, Volume 18, Issue 7-8 (2022)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Drug Metabolism & Toxicology, Volume 18, Issue 7-8 (2022)

See all volumes and issues
Vol 20, 2024 Vol 19, 2023 Volume 18, 2022 Vol 17, 2021 Vol 16, 2020 Vol 15, 2019 Vol 14, 2018 Vol 13, 2017 Vol 12, 2016 Vol 11, 2015 Vol 10, 2014 Vol 9, 2013 Vol 8, 2012 Vol 7, 2011 Vol 6, 2010 Vol 5, 2009 Vol 4, 2008 Vol 3, 2007 Vol 2, 2006 Vol 1, 2005
Download citations Download PDFs Download issue

Review

Review
Cardiomyocyte-specific CYP2J2 and its therapeutic implications
Robert Valencia, Wesam Bassiouni, Ahmed M. Darwesh, Raj Bapuji & John M. Seubert
Pages: 423-439
Published online: 09 Sep 2022
AbstractforCardiomyocyte-specific CYP2J2 and its therapeutic implications | Full Text | References | PDF (3.3 MB) | EPUB
  • 379 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids
Giulio Evangelisti, Fabio Barra, Umberto Perrone, Nadine Di Donato, Stefano Bogliolo, Marcello Ceccaroni & Simone Ferrero
Pages: 441-457
Published online: 23 Aug 2022
AbstractforComparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids | Full Text | References | PDF (1.7 MB) | EPUB
  • 369 Views
  • 2 CrossRef citations
  • 0Altmetric
Review
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature
Nadeen Anabtawi, Thomas Drabison, Shuiying Hu, Alex Sparreboom & Zahra Talebi
Pages: 459-468
Published online: 30 Aug 2022
AbstractforThe role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature | Full Text | References | PDF (1 MB) | EPUB
  • 2632 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Review
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury
Robert A. Roth, Omar Kana, David Filipovic & Patricia E. Ganey
Pages: 469-481
Published online: 24 Aug 2022
AbstractforPharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury | Full Text | References | PDF (4.3 MB) | EPUB
  • 1360 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Review
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs
Mengbi Yang & Xin Xu
Pages: 483-505
Published online: 09 Sep 2022
AbstractforImportant roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs | Full Text | References | PDF (1.8 MB) | EPUB
  • 1231 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Review
Comorbidities and the right dose: antipsychotics
Nicolas Simon, Romain Torrents & Jean-Michel Azorin
Pages: 507-518
Published online: 22 Aug 2022
AbstractforComorbidities and the right dose: antipsychotics | Full Text | References | PDF (773.2 KB) | EPUB
  • 286 Views
  • 1 CrossRef citations
  • 0Altmetric

Original Research

Article
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects
Zhengzhi Liu, Zhenyue Gao, Wei Yang, Lixiu Zhang, Nan Xiao, Dongmei Qu, Zhengjie Su, Kaibo Xu, Guangwen Liu, Yanli Wang, Qing Ren, Shuang Yu, Yang Cheng, Yannan Zhou, Qiaohuan Deng, Yicheng Zhao, Zeyu Wang & Haimiao Yang
Pages: 519-527
Published online: 18 Aug 2022
AbstractforA randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects | Full Text | References | PDF (422.3 KB) | EPUB | Supplemental
  • 169 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro
Yuan Gao & Jingjing Ma
Pages: 529-535
Published online: 17 Aug 2022
AbstractforCytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro | Full Text | References | PDF (558.6 KB) | EPUB
  • 88 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Recent progress in machine learning approaches for predicting carcinogenicity in drug development
Nguyen Quoc Khanh Le et al.
Review Article | Published online: 27 May 2024
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact
Lorenzo Gasperoni et al.
Review Article | Published online: 22 May 2024
Open Access
The role of the circadian timing system on drug metabolism and detoxification: an update
Alper Okyar et al.
Review Article | Published online: 20 May 2024
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s
Tanya Song et al.
Review Article | Published online: 20 May 2024
View all latest articles